Skip to Main Content

Paper Details

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Eur J Heart Fail
168
2021
Dapagliflozin, Heart Failure, Patients, SGLT2, Sodium-, Sodium-glucose, Sodium-glucose co-transporter 2, cardiovascular death, chronic heart failure, dapagliflozin, diabetes, glucose, heart failure, natriuretic peptides, patients, structural heart disease, type 2 diabetes
Author NameAffiliation
Rudolf A de BoerUniversity of Groningen
David L DeMetsUniversity of Wisconsin
David L DeMetsUniversity of Wisconsin
Adrian F HernandezDuke University Medical Center
Mikhail KosiborodSaint Luke's Mid America Heart Institute
Carolyn S P LamUniversity of Groningen
Carolyn S P LamNational Heart Centre Singapore & Duke-National University of Singapore
  • 1 - 7

Datasets

Release 1.2